Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy

[1]  Joseph B Hiatt,et al.  Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T cell killing. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  Ş. Turcan,et al.  Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas , 2022, International journal of cancer.

[3]  Amit Verma,et al.  Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions , 2021, Clinical Cancer Research.

[4]  B. Jha,et al.  PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation , 2021, Cell reports.

[5]  C. Paweletz,et al.  Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity. , 2021, Cancer discovery.

[6]  Y. Saunthararajah,et al.  A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. , 2020, Seminars in hematology.

[7]  J. Maciejewski,et al.  Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network , 2020, Leukemia.

[8]  Y. Saunthararajah.  Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation , 2020, Haematologica.

[9]  J. Maciejewski,et al.  Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies , 2019, British journal of haematology.

[10]  T. Jacks,et al.  Identification of DHODH as a therapeutic target in small cell lung cancer , 2019, Science Translational Medicine.

[11]  J. Peters,et al.  Self-organization of parS centromeres by the ParB CTP hydrolase , 2019, Science.

[12]  R. Tothill,et al.  An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer , 2019, Cancer cell.

[13]  Irving L. Weissman,et al.  A molecular cell atlas of the human lung from single cell RNA sequencing , 2019, Nature.

[14]  H. Clevers,et al.  Identification of Enteroendocrine Regulators by Real-Time Single-Cell Differentiation Mapping , 2019, Cell.

[15]  M. Dietel,et al.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal , 2018, Modern Pathology.

[16]  B. Porse,et al.  Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates , 2018, The Journal of clinical investigation.

[17]  D. Spector,et al.  POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer , 2018, Genes & development.

[18]  P. Chow,et al.  GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. , 2017, The Journal of clinical investigation.

[19]  J. Ranish,et al.  Loss of Snf5 Induces Formation of an Aberrant SWI/SNF Complex. , 2017, Cell reports.

[20]  R. Ferris,et al.  Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer , 2017, Oncoimmunology.

[21]  J. Strouboulis,et al.  Distinct and overlapping DNMT1 interactions with multiple transcription factors in erythroid cells: Evidence for co-repressor functions. , 2016, Biochimica et biophysica acta.

[22]  Luc Girard,et al.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.

[23]  Klaus Hansen,et al.  An interactive environment for agile analysis and visualization of ChIP-sequencing data , 2016, Nature Structural &Molecular Biology.

[24]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[25]  C. Nervi,et al.  Epigenetic treatment of solid tumours: a review of clinical trials , 2015, Clinical Epigenetics.

[26]  John T. Poirier,et al.  DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2 , 2015 .

[27]  M. Pappalardi,et al.  A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. , 2015, Cancer cell.

[28]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[29]  J. Maciejewski,et al.  Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. , 2015, The Journal of clinical investigation.

[30]  Tao Wang,et al.  ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers , 2014, Proceedings of the National Academy of Sciences.

[31]  Y. Saunthararajah,et al.  Runx1 Regulation of Pu.1 Corepressor/Coactivator Exchange Identifies Specific Molecular Targets for Leukemia Differentiation Therapy* , 2014, The Journal of Biological Chemistry.

[32]  Y. Saunthararajah,et al.  Subchronic Oral Toxicity Study of Decitabine in Combination With Tetrahydrouridine in CD-1 Mice , 2014, International journal of toxicology.

[33]  Haroon Naeem,et al.  Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array , 2014, BMC Genomics.

[34]  R. Rintoul,et al.  CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. , 2014, Cancer research.

[35]  Pu Zhang,et al.  DNMT1-interacting RNAs block gene specific DNA methylation , 2013, Nature.

[36]  Michael Q. Zhang,et al.  Epigenomic Analysis of Multilineage Differentiation of Human Embryonic Stem Cells , 2013, Cell.

[37]  X. Sun,et al.  Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells , 2013, Cell Death and Disease.

[38]  Y. Saunthararajah,et al.  High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects , 2012, Oncotarget.

[39]  Julie V. Harness,et al.  Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives. , 2012, Cell stem cell.

[40]  I. Kubacka,et al.  Mutant p53 cooperates with ETS2 to promote etoposide resistance. , 2012, Genes & development.

[41]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[42]  Kwok-Kin Wong,et al.  Characterization of the cell of origin for small cell lung cancer , 2011, Cell cycle.

[43]  Reinhold Munker,et al.  RUNX1 regulates corepressor interactions of PU.1. , 2011, Blood.

[44]  T. Gerds,et al.  PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53 , 2011, Clinical Cancer Research.

[45]  J. Maciejewski,et al.  p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia , 2011, Leukemia.

[46]  Stuart H. Orkin,et al.  A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs , 2010, Cell.

[47]  M. Brock,et al.  Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. , 2009, Cancer research.

[48]  Ming Zhao,et al.  Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura , 2006, Clinical Cancer Research.

[49]  Y. Yatabe,et al.  ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. , 2005, Cancer research.

[50]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[51]  S. Baylin,et al.  An achaete-scute homologue essential for neuroendocrine differentiation in the lung , 1997, Nature.

[52]  J. Roth,et al.  Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. , 1994, Cancer research.

[53]  F. Hirsch,et al.  Metastatic patterns in small-cell lung cancer: correlation of autopsy findings with clinical parameters in 537 patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  OUP accepted manuscript , 2022, Nucleic Acids Research.

[55]  Jacob D. Jaffe,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[56]  Lee,et al.  Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 , 2016 .